

# Lawrence Blonde

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7416560/publications.pdf>

Version: 2024-02-01

95  
papers

7,995  
citations

147801

31  
h-index

48315

88  
g-index

98  
all docs

98  
docs citations

98  
times ranked

7533  
citing authors

#	ARTICLE	IF	CITATIONS
1	Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results. <i>Diabetes Therapy</i> , 2022, 13, 205-215.	2.5	5
2	A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 979-994.	5.7	13
3	Editorial Cycles and Continuity of <i>Diabetes Care</i> . <i>Diabetes Care</i> , 2022, 45, 1493-1494.	8.6	0
4	Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States. <i>Advances in Therapy</i> , 2021, 38, 594-606.	2.9	5
5	Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes. <i>Advances in Therapy</i> , 2021, 38, 1715-1731.	2.9	6
6	Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1331-1341.	4.4	2
7	Insulin glargine 300%units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1713-1721.	4.4	5
8	Improving Management of Type 2 Diabetes Using Home-Based Telemonitoring: Cohort Study. <i>JMIR Diabetes</i> , 2021, 6, e24687.	1.9	10
9	Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2234-2241.	4.4	2
10	Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. <i>Diabetes Care</i> , 2021, 44, 774-780.	8.6	6
11	A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes. <i>Diabetes Care</i> , 2021, 44, 8-10.	8.6	8
12	Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2179-2188.	4.4	14
13	Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study. <i>Diabetes Therapy</i> , 2020, 11, 2629-2645.	2.5	14
14	Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo. <i>Postgraduate Medicine</i> , 2020, 132, 15-25.	2.0	8
15	Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and Consequences. <i>Diabetes Spectrum</i> , 2020, 33, 8-15.	1.0	25
16	Insulin glargine 300%U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1995-2003.	4.4	10
17	Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L. <i>Diabetes Therapy</i> , 2020, 11, 1007-1015.	2.5	5
18	Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2170-2178.	4.4	11

#	ARTICLE	IF	CITATIONS
19	Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 929-937.	4.4	29
20	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 107-139.	2.1	410
21	Impact of disease duration and Î²-cell reserve on the efficacy of switching to <sc>iGlarLixi</sc> in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the <sc>LixiLan-G</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1567-1576.	4.4	9
22	Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. <i>Advances in Therapy</i> , 2019, 36, 2310-2326.	2.9	2
23	Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2384-2393.	4.4	25
24	Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. <i>Diabetes Care</i> , 2019, 42, 2108-2116.	8.6	50
25	Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice. <i>Diabetes Spectrum</i> , 2019, 32, 93-103.	1.0	15
26	Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1596-1605.	4.4	25
27	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. <i>Endocrine Practice</i> , 2019, 25, 69-101.	2.1	245
28	Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2019, 35, 793-804.	1.9	22
29	OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
30	Real-world evidence in diabetes: relevance to clinical practice. <i>Journal of Family Practice</i> , 2019, 68, .	0.2	2
31	Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin. <i>Diabetes Therapy</i> , 2018, 9, 1169-1184.	2.5	18
32	The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population. <i>Current Medical Research and Opinion</i> , 2018, 34, 1501-1511.	1.9	4
33	Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1293-1297.	4.4	63
34	A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin. <i>Current Medical Research and Opinion</i> , 2018, 34, 1143-1152.	1.9	10
35	Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA. <i>Diabetes Therapy</i> , 2018, 9, 1347-1358.	2.5	47
36	Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: <sc>A</sc> real-world study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1722-1731.	4.4	12

#	ARTICLE	IF	CITATIONS
37	Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 921-929.	4.4	5
38	Glucagon-Like Peptide 1 Receptor Agonists For Type 2 Diabetes: A Comprehensive Review of How to Weigh The Options, Select the Right Patients, and Maximize Benefits. <i>Endocrine Practice</i> , 2018, 24, 8-19.	2.1	1
39	Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. <i>Advances in Therapy</i> , 2018, 35, 1763-1774.	2.9	424
40	Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations. <i>Advances in Therapy</i> , 2018, 35, 939-965.	2.9	14
41	Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2148-2158.	4.4	59
42	Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology. <i>Diabetes Care</i> , 2018, 41, 1327-1329.	8.6	4
43	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. <i>Endocrine Practice</i> , 2018, 24, 91-121.	2.1	388
44	From Randomized Controlled Trials to the Real World: Putting Evidence into Context. <i>Journal of Family Practice</i> , 2018, 67, S55-S60.	0.2	2
45	<i>Diabetes Care</i>: “Taking It to the Limit One More Time” <i>Diabetes Care</i> , 2017, 40, 3-6.	8.6	7
46	Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. <i>Cardiovascular Diabetology</i> , 2017, 16, 6.	6.8	107
47	Gaps and barriers in the control of blood glucose in people with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 172-183.	2.0	102
48	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary. <i>Endocrine Practice</i> , 2017, 23, 207-238.	2.1	362
49	Lixisenatide as add-on treatment among patients with different $\beta$ -cell function levels as assessed by HOMA $\beta$ index. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2897.	4.0	13
50	Insulin regimens and glycemic control in different parts of Europe over 4 years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study. <i>Diabetes Research and Clinical Practice</i> , 2017, 133, 150-158.	2.8	6
51	Predictors of outcomes in patients with type 2 diabetes in the lixisenatide <sc>GetGoal</sc> clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 275-283.	4.4	13
52	Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , 2016, 22, 84-113.	2.1	405
53	Getting to the “Heart” of the Matter on Diabetic Cardiovascular Disease: “Thanks for the Memory” <i>Diabetes Care</i> , 2016, 39, 664-667.	8.6	17
54	A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures. <i>BMC Health Services Research</i> , 2016, 16, 356.	2.2	6

#	ARTICLE	IF	CITATIONS
55	Diabetes Care: "Lagniappe" and "Seeing Is Believing". Diabetes Care, 2016, 39, 1069-1071.	8.6	1
56	Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone. Clinical Drug Investigation, 2016, 36, 293-303.	2.2	11
57	Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine, 2016, 128, 371-380.	2.0	55
58	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan " 2015. Endocrine Practice, 2015, 21, 1-87.	2.1	443
59	American Association of Clinical Endocrinologists and American College of Endocrinology " Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan " 2015 " Executive Summary. Endocrine Practice, 2015, 21, 413-437.	2.1	359
60	Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2015, 2015, 1-13.	2.3	29
61	Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet, The, 2015, 385, 2057-2066.	13.7	180
62	Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials. Clinical Therapeutics, 2015, 37, 1045-1054.	2.5	10
63	Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2015, 29, 438-444.	2.3	43
64	Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia, 2015, 58, 1183-1187.	6.3	118
65	Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovascular Diabetology, 2015, 14, 12.	6.8	62
66	Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Current Medical Research and Opinion, 2015, 31, 1993-2000.	1.9	10
67	Identifying Risk Factors for Severe Hypoglycemia in Hospitalized Patients with Diabetes. Endocrine Practice, 2014, 20, 1051-1056.	2.1	29
68	Fixed-Dose Combination Therapy in Type 2 Diabetes Mellitus. Endocrine Practice, 2014, 20, 1322-1332.	2.1	23
69	Efficacy and Risk of Hypoglycemia With Use of Insulin Glargine or Comparators in Patients With Cardiovascular Risk Factors. Postgraduate Medicine, 2014, 126, 172-189.	2.0	5
70	Aace Comprehensive Diabetes Management Algorithm 2013. Endocrine Practice, 2013, 19, 327-336.	2.1	318
71	Benefits and Risks for Intensive Glycemic Control in Patients With Diabetes Mellitus. American Journal of the Medical Sciences, 2012, 343, 17-20.	1.1	37
72	Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus. Advances in Therapy, 2012, 29, 1-13.	2.9	55

#	ARTICLE	IF	CITATIONS
73	Achieving antihyperglycemic treatment goals with incretin-related therapies. American Journal of Managed Care, 2012, 18, S219-27.	1.1	2
74	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. Endocrine Practice, 2011, 17, 1-53.	2.1	387
75	Improving care for patients with type 2 diabetes: applying management guidelines and algorithms, and a review of new evidence for incretin agents and lifestyle intervention. American Journal of Managed Care, 2011, 17 Suppl 14, S368-76.	1.1	3
76	Current Antihyperglycemic Treatment Guidelines and Algorithms for Patients with Type 2 Diabetes Mellitus. American Journal of Medicine, 2010, 123, S12-S18.	1.5	59
77	Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD). Diabetes Care, 2009, 32, 1224-1230.	8.6	768
78	Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, The, 2009, 374, 39-47.	13.7	1,324
79	Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleveland Clinic Journal of Medicine, 2009, 76, S4-S11.	1.3	33
80	Adherence to Practice Guidelines for People with Diabetes Mellitus. , 2008, , 235-249.		1
81	Easing the Transition to Insulin Therapy in People With Type 2 Diabetes. The Diabetes Educator, 2007, 33, 232S-240S.	2.5	1
82	Case Presentation. The Diabetes Educator, 2007, 33, 114S-116S.	2.5	0
83	State of diabetes care in the United States. American Journal of Managed Care, 2007, 13 Suppl 2, S36-40.	1.1	10
84	Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials*. Current Medical Research and Opinion, 2006, 22, 2111-2120.	1.9	27
85	Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?. Expert Review of Cardiovascular Therapy, 2006, 4, 871-895.	1.5	89
86	Internet Resources to Improve Health Care for Patients with Diabetes. Endocrine Practice, 2006, 12, 131-137.	2.1	13
87	What Are Incretins, and How Will They Influence the Management of Type 2 Diabetes?. Journal of Managed Care Pharmacy, 2006, 12, 1-16.	2.2	4
88	Reducing cardiovascular disease risk in patients with diabetes: A message from the National Diabetes Education Program. Journal of the American Academy of Nurse Practitioners, 2006, 18, 524-533.	1.4	9
89	Current challenges in diabetes management. Clinical Cornerstone, 2005, 7, S6-S17.	0.7	32
90	Current evidence regarding the value of self-monitored blood glucose testing. American Journal of Medicine, 2005, 118, 20-26.	1.5	74

#	ARTICLE	IF	CITATIONS
91	Patient management strategies in type 2 diabetes: current practices and future considerations. Journal of Managed Care Pharmacy, 2005, 11, S12-8.	2.2	2
92	Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Current Medical Research and Opinion, 2004, 20, 565-572.	1.9	111
93	New concepts in diabetes: how multihormonal regulation can improve glycemic control. Journal of Managed Care Pharmacy, 2004, 10, S3-8; quiz S9, S11-2.	2.2	24
94	Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. American Journal of Clinical Nutrition, 2000, 71, 1433-1438.	4.7	141
95	DEFINING AND MEASURING QUALITY OF DIABETES CARE. Primary Care - Clinics in Office Practice, 1999, 26, 841-855.	1.6	10